Physician profile
Stephen L Brewbaker
NPI 1104979467
$1,903.53
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $979 · 2020: $536 · 2021: $388.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $468.21 | 2019-2021 | |
| Abbvie INC. | $358.04 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $355.07 | 2019-2020 | |
| Lilly USA, LLC | $115.85 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $112.82 | 2019 | |
| Therapeuticsmd, INC. | $105.77 | 2019 | |
| Avion Pharmaceuticals | $101.49 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $86.84 | 2020-2021 | |
| Eisai INC. | $45.75 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $44.18 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $29.80 | 2020 | |
| Allergan, INC. | $23.57 | 2020 | |
| Duchesnay USA Incorporated | $15.74 | 2019 | |
| Upsher-Smith Laboratories LLC | $15.24 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.77 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $12.39 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Brewbaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.